CORT Stock Overview
Engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Corcept Therapeutics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.09 |
| 52 Week High | US$61.66 |
| 52 Week Low | US$20.84 |
| Beta | 0.46 |
| 11 Month Change | 14.21% |
| 3 Month Change | 63.62% |
| 1 Year Change | 121.35% |
| 33 Year Change | 149.73% |
| 5 Year Change | 324.60% |
| Change since IPO | 358.63% |
Recent News & Updates
Recent updates
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Sep 28
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity
Sep 06Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)
Aug 01With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For
Apr 15We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit
Feb 22Corcept Therapeutics: Key Catalysts Ahead
Feb 19After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar
Dec 23Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price
Nov 07Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?
Jun 23Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Feb 16Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today
Jan 11Corcept Therapeutics starts phase 2 trial of its ALS treatment
Oct 11Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?
Sep 27Shareholder Returns
| CORT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.6% | -5.3% | -1.2% |
| 1Y | 121.3% | 8.7% | 30.4% |
Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: CORT exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| CORT volatility | |
|---|---|
| CORT Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CORT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CORT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 352 | Joseph Belanoff | www.corcept.com |
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
Corcept Therapeutics Incorporated Fundamentals Summary
| CORT fundamental statistics | |
|---|---|
| Market cap | US$5.69b |
| Earnings (TTM) | US$140.49m |
| Revenue (TTM) | US$628.56m |
41.8x
P/E Ratio9.3x
P/S RatioIs CORT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CORT income statement (TTM) | |
|---|---|
| Revenue | US$628.56m |
| Cost of Revenue | US$9.80m |
| Gross Profit | US$618.75m |
| Other Expenses | US$478.27m |
| Earnings | US$140.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.34 |
| Gross Margin | 98.44% |
| Net Profit Margin | 22.35% |
| Debt/Equity Ratio | 0% |
How did CORT perform over the long term?
See historical performance and comparison